Article
Clinical Neurology
Meritxell Tost, Alex Gonzalez-Rodriguez, Raquel Aguayo, Aida Alvarez, Itziar Montalvo, Juan David Barbero, Rosa Gabernet, Eduard Izquierdo, Igor Merodio, Jose Antonio Monreal, Diego Palao, Javier Labad
Summary: Switching from risperidone to paliperidone palmitate may be associated with improved social functioning and cognitive abilities in patients with schizophrenia.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2023)
Review
Multidisciplinary Sciences
Andre L. Mihaljevic, Colette Doerr-Harim, Eva Kalkum, Guido Strunk
Summary: This study conducted a systematic review and quality analysis of German-language PREMs, revealing that none of the included PREMs cover all aspects of patient centeredness. The EORTC IN-PATSAT32 and PSCC-G are recommended for cancer patients in the German-language region, while the German versions of HCAHPS, NORPEQ, PPE-15, and PEACS can be recommended as generic PREMs.
Article
Clinical Neurology
Sofia Pappa, Joshua Barnett, Katy Mason
Summary: This 10-year follow-up study on the use of paliperidone palmitate once monthly (PP1M) showed that long-term treatment with PP1M can improve hospitalization rates and duration of admissions in schizophrenic and psychotic patients. The study findings suggest the potential for cost-effectiveness and facilitate shared decision making.
Review
Oncology
C. F. Davies, R. Macefield, K. Avery, J. M. Blazeby, S. Potter
Summary: This systematic review evaluated the development and measurement properties of existing BR patient-reported outcome measures (PROMs) and found that BREAST-Q, BRECON-31, and EORTC QLQ-BRECON-23 have adequate content validity and quality for inclusion in a core measurement set. Discussion with stakeholders is needed to reach a consensus on the recommended PROM for future studies.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Neurosciences
Sidhant Chopra, Alex Fornito, Shona M. Francey, Brian O'Donoghue, Vanessa Cropley, Barnaby Nelson, Jessica Graham, Lara Baldwin, Steven Tahtalian, Hok Pan Yuen, Kelly Allott, Mario Alvarez-Jimenez, Susy Harrigan, Kristina Sabaroedin, Christos Pantelis, Stephen J. Wood, Patrick McGorry
Summary: This study aimed to differentiate between illness-related brain volume changes and medication-related changes within the first 3 months of treatment. It was found that antipsychotic medication and placebo had different effects on the pallidum volume, with patients showing increased volume and healthy controls showing no change. This suggests that psychotic illness and antipsychotic exposure have distinct effects on brain volume.
NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Clinical Neurology
Mingjun Zhao, Bin Qin, Yage Mao, Yang Zhang, Ruisheng Zhao, Aiqin Wang, Hailing Wang, Jianting Zhao, Changhong Wang
Summary: The purpose of this study was to compare the efficacy and safety of paliperidone palmitate (PP) treatment with risperidone long-acting injectable (LAI) treatment for patients with schizophrenia. A meta-analysis of published randomized controlled trials was conducted, and the results showed that there were no significant differences in efficacy between PP and risperidone-LAI treatments, but PP had some safety risks.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Gastroenterology & Hepatology
Marguerite J. Kutyla, Jessica J. McMaster, Adam Haig, Natasha Koloski, Luke Hourigan, Vera Meeusen, Ayesha Shah, Nicholas J. Talley, Michael P. Jones, Gerald J. Holtmann
Summary: This study aimed to develop and validate a patient-reported experience measure for GI endoscopy. The Comprehensive Endoscopy Satisfaction Tool captures relevant domains that influence the patient's experience and identifies factors that shape satisfaction. The tool was tested in a large number of patients and found to be valid and responsive.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Juan J. Fernandez-Miranda, Silvia Diaz-Fernandez, Domenico De Berardis, Francisco Lopez-Munoz
Summary: Paliperidone palmitate every three months (PP3M) was found to improve treatment compliance, satisfaction, effectiveness, and tolerability in patients with severe schizophrenia compared to paliperidone palmitate monthly (PP1M). Although some patients switched back to PP1M due to adverse effects, overall, PP3M treatment increased patient satisfaction and adherence, with lower incidence of side effects.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medical Informatics
Samantha Cruz Rivera, Xiaoxuan Liu, Sarah E. Hughes, Helen Dunster, Elaine Manna, Alastair K. Denniston, Melanie J. Calvert
Summary: Integration of patient-reported outcome measures (PROMs) in artificial intelligence (AI) studies is crucial for humanizing AI in healthcare. Despite challenges such as data fragmentation, limited validation, and inadequate selection of PROMs, considerations for including PROs in AI healthcare technologies are proposed to ensure the overall well-being of patients.
LANCET DIGITAL HEALTH
(2023)
Article
Medicine, General & Internal
Alexander Hodkinson, Carl Heneghan, Kamal R. Mahtani, Evangelos Kontopantelis, Maria Panagioti
Summary: Risperidone and Paliperidone are treatments for schizophrenia or bipolar disorder. Meta-analysis shows that these antipsychotics have a small beneficial effect on reducing PANSS score over 9 weeks, which is more conservative than estimates based on journal publications. Clinical study reports contain significantly more data on harms that were unavailable in journal publications or trial registries.
Article
Medicine, General & Internal
Jeffrey Frankel, Susann Varano, David Staskin, Denise Shortino, Rachael Jankowich, Paul N. Mudd
Summary: The 12-week EMPOWUR trial showed that treatment with vibegron was associated with significantly greater and clinically meaningful improvement in QOL and OAB symptoms compared to placebo, especially in coping, sleep, and health-related QOL.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Public, Environmental & Occupational Health
Tao Han, Sisi Li, Xueyuan Li, Chenhao Yu, Jiahui Li, Tiantian Jing, Mayangzong Bai, Yue Fang, Kun Qian, Xiaoyan Li, Huigang Liang, Zhiruo Zhang
Summary: This study introduces the patient-centered approach in China and validates the Chinese version of the Patient-Professional Interaction Questionnaire (PPIQ-C) to assess patient satisfaction. The results show that the PPIQ-C is a reliable measure and patient-centered care predicts overall patient satisfaction beyond other medical service perspectives. Adopting a patient-centered approach can improve overall healthcare and patient satisfaction in China.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Gastroenterology & Hepatology
Anika Varma, Jennifer Weinstein, Jamison Seabury, Spencer Rosero, Ellen Wagner, Christine Zizzi, Elizabeth Luebbe, Nuran Dilek, Michael McDermott, John Heatwole, Lawrence Saubermann, Larissa Temple, Scott Rogoff, Chad Heatwole
Summary: This study aimed to identify the most prevalent and impactful symptoms in patients with Crohn's disease (CD) and to determine the modifying factors associated with a higher disease burden in CD.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Oncology
Pauline Duerr, Katja Schlichtig, Carolin Kelz, Birgit Deutsch, Renke Maas, Michael J. Eckart, Jochen Wilke, Harald Wagner, Kerstin Wolff, Caroline Preuss, Valeska Brueckl, Norbert Meidenbauer, Christian Staerk, Andreas Mayr, Rainer Fietkau, Peter J. Goebell, Frank Kunath, Matthias W. Beckmann, Andreas Mackensen, Markus F. Neurath, Marianne Pavel, Frank Doerje, Martin F. Fromm
Summary: Treatment with oral anticancer drugs is associated with a wide range of medication errors and side effects. Intensified clinical pharmacological/pharmaceutical care has significant positive effects on reducing medication errors, improving patient treatment perception, and decreasing severe side effects.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Ophthalmology
Eugene R. Declercq, Howard J. Cabral, Xiaohui Cui, Chia-Ling Liu, Ndidiamaka Amutah-Onukagha, Elysia Larson, Audra Meadows, Hafsatou Diop
Summary: This study evaluated visual performance and patient-reported outcomes after bilateral implantation of a new nondiffractive wavefront-shaping extended depth-of-focus intraocular lens. The results showed that this IOL provides good visual acuity at far and intermediate distance, with good quality of vision and contrast sensitivity, and high spectacle independence for distance and intermediate vision.
JOURNAL OF CATARACT AND REFRACTIVE SURGERY
(2022)